PR Newswire·Nov 10, 2026, 6:45 AM ET

Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results

Protalix BioTherapeutics reported total revenues of $75.6 million for the first nine months of 2026, an increase of $32.0 million from the same period in 2025.
Net income for the third quarter of 2026 was $4.0 million, compared to $2.4 million in the third quarter of 2025.
Net income for the nine months ended September 30, 2026, reached $26.1 million, reversing a net loss of $1.1 million in the prior-year period.
The company expects to meet or exceed 2026 revenue guidance of approximately $78.0 million to $83.0 million.
Cash, cash equivalents, and short-term bank deposits totaled $48.5 million as of September 30, 2026.
Elfabrio received marketing authorization in Brazil for both every-two-weeks and every-four-weeks dosing regimens.
The Phase 2 RELEASE study for PRX-115 to treat uncontrolled gout is on track, with top-line results anticipated in the second half of 2027.
New individual patient data presented at ACR Convergence 2026 shows PRX-115 plasma levels remained measurable for up to 85 days.
The company reaffirmed full-year 2026 revenue projections, including a $25.0 million milestone payment from Chiesi received in Q1 2026.
Protalix reported no outstanding debt or warrants and continues to advance its rare renal programs, including PRX-119.
A conference call to review financial results is scheduled for November 10, 2026, at 8:00 a.m. ET.